ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Last updated: March 14, 2017
Sponsor: Merck Sharp & Dohme Corp.
Overall Status: Completed

Phase

3

Condition

Herpes Simplex Infections

Chickenpox (Varicella Zoster Infection)

Pneumococcal Disease

Treatment

N/A

Clinical Study ID

NCT00535730
V211-012
2007_592
  • Ages > 60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 60 years of age or older

  • Stable underlying conditions

  • Postmenopausal if female

  • Afebrile

Exclusion

Exclusion Criteria:

  • Previously vaccinated with either vaccine

  • Immune deficiency

  • History of allergy to components in either vaccine

  • Concomitant antiviral therapy

Study Design

Total Participants: 473
Study Start date:
June 01, 2007
Estimated Completion Date:
February 29, 2008